Opendata, web and dolomites

TRACER SIGNED

TRAF-STOP therapy to reduCe inflammation in athERosclerosis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRACER project word cloud

Explore the words cloud of the TRACER project. It provides you a very rough idea of what is the project "TRACER" about.

interaction    investment    hypothesis    reduce    stops    oral    patent    translational    dyad    termed    atherosclerosis    solid    mice    force    driving    found    screening    cartesio    portfolio    suppression    tested    inflammatory    mediators    co    traf6    ing    small    prof    inhibition    signaling    mini    cd40    poc    molecule    hold    pursue    inhibitors    pipeline    majority    relative    bio    traf    vast    virtual    ligand    founders    thromboembolic    clinical    start    lutgens    valorise    pass    therapeutic    treatment    risk    reduces    characterizing    domain    atherosclerotic    underlying    significantly    plan    seed    tnf    disease    treat    business    model    capital    downstream    25    implications    animal    ready    arteries    excellent    stimulatory    poses    company    candidates    diseases    hands    toxicology    cd40l    binding    drug    lowering    pig    immune    despite    unaddressed    blocking    first    grant    tolerated    modeled    events    venture    bind    scientific    lipid    receptor    therapeutics    cardiovascular   

Project "TRACER" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM 

Organization address
address: MEIBERGDREEF 15
city: AMSTERDAM
postcode: 1105AZ
website: www.amc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) coordinator 150˙000.00

Map

 Project objective

Atherosclerosis, the underlying cause of the majority of cardiovascular diseases, is a lipid driven, inflammatory disease of the large arteries. Despite a 25% relative risk reduction achieved by lipid-lowering treatment, the vast majority of atherosclerosis induced cardiovascular disease risk remains unaddressed. Therefore, characterizing mediators of the inflammatory aspect of atherosclerosis is a widely recognized scientific goal with great therapeutic implications. Blocking the co-stimulatory CD40L-CD40 dyad reduces atherosclerosis. However, long-term inhibition of CD40L or its receptor CD40 results in suppression of the immune system and poses a risk for thromboembolic events. Therefore, we focused on the downstream signaling pathways of CD40, and found that the interaction between CD40 and TNF-receptor-associated factor 6 (TRAF6) is the driving force for atherosclerosis. Using virtual ligand screening, we identified several small molecule inhibitors termed TRAF-STOPs that were modeled to bind to the CD40-binding domain of TRAF6. TRAF-STOPs significantly reduce (existing) atherosclerosis and treatment was well tolerated. The first toxicology results in mice show that there are no side effects. Here we pursue the hypothesis that TRAF-STOPs are excellent candidates to pass the translational pipeline towards a clinical application to treat atherosclerotic cardiovascular disease. Prof. Lutgens is one of the founders of the recently established start-up company Cartesio Therapeutics to be able to valorise our novel TRAF-STOPs. By the end of the PoC grant, we expect to have an oral drug available and to have completed toxicology and bio-distribution analysis in a large animal model (mini-pig) and have tested TRAF-STOPs in a pig model of atherosclerosis. This way, we hold a solid business case in our hands. The resulting business- and (pre-)clinical development plan and patent portfolio will then be ready for seed investment and venture capital funding.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRACER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRACER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

E-DIRECT (2020)

Evolution of Direct Reciprocity in Complex Environments

Read More  

TORYD (2020)

TOpological many-body states with ultracold RYDberg atoms

Read More  

ARCTIC (2020)

Air Transport as Information and Computation

Read More